<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Simultaneous intraocular and cutaneous extranodal NK/T-cell lymphoma refractory to multiple therapies including pembrolizumab.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Simultaneous intraocular and cutaneous extranodal NK/T-cell lymphoma refractory to multiple therapies including pembrolizumab." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49d9/8133067/6d4a00a32f8b/CCR3-9-e04194-g002.jpg"/> </div> <div class="text-side"> <h1>Simultaneous intraocular and cutaneous extranodal NK/T-cell lymphoma refractory to multiple therapies including pembrolizumab.</h1> <p>Skin biopsy histopathology and immunochemistry (A) Diffuse dermal and subcutaneous infiltrate of lymphoma cells (H and E, x20). (B) Higher magnification demonstrating medium to large in size pleomorphic lymphoma cells with hyperchromatic nuclei and irregular nuclear outlines (H and E x400). (C) Prominent involvement of the subcutaneous fat in a pattern reminiscent of lobular panniculitis. (D) Epstein‐Barr Virus Encoded RNA (EBER) expression of lymphoma cells, with perivascular (red arrow) and perineurial (blue arrow) distribution. (E) Diffuse nuclear expression of GATA3 by the lymphoma cells in the subcutis. (F) Strong expression of cytotoxic proteins including granzyme (demonstrated here), TIA‐1, and perforin</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34026185/" target="_blank">34026185</a></p><p>Type: Premalignant/Malignant, Category: Hematolymphoid</p>
</div> </div></div></body></html>